Purpose: Access to claims databases provides an opportunity to study medication use and safety during pregnancy. We developed an algorithm to identify pregnancy episodes in the French health care databases and applied it to study antiepileptic drug (AED) use during pregnancy between 2007 and 2014.
| INTRODUCTION
The exclusion of pregnant women from clinical trials results in a lack of information about the effects of medication use during pregnancy on maternal and fetal health. Access to claims databases therefore provides an opportunity to study medication use and safety during pregnancy. These databases are particularly useful, as these studies, often concerning rare exposures and rare birth outcomes, require large data sources. Routine post-marketing research is also possible, since information on a wide range of outcomes and all prescription drugs prescribed or dispensed during pregnancy is available. Ascertainment of medication use is based on pharmacy claims data and is independent of maternal or infant outcomes, which avoids parental recall bias. 1 However, claims databases are usually not built for research purposes and algorithmic approaches must be developed in order to identify pregnancy episodes and related outcomes. 2 A few articles have been specifically devoted to this challenge, using the Clinical Practice
Research Datalink 2, 3 or North American claims databases. 1, [4] [5] [6] [7] [8] In
France, despite growing interest in pregnancy research using claims databases, [9] [10] [11] [12] [13] [14] [15] [16] no algorithm has yet been published. However, some studies have explicitly reported the discharge diagnoses or medical procedures used to identify pregnancies. [9] [10] [11] 13, 16 Most studies were restricted to births, and only a few studies included abortion and ectopic pregnancies. 9, 12, 14, 16 The primary objective of this study was therefore to develop an algorithm to identify pregnancy episodes and related outcomes using the French health care databases, which covers 99% of the 67 million inhabitants in France. 17 The secondary objective was to apply this algorithm to the analysis of antiepileptic drug (AED) use during pregnancy in
France between 2007 and 2014. Studying AED use during pregnancy is of particular interest, as prenatal exposure to some older AEDs has been found to be associated with increased risks of major congenital malformations, 18 and prenatal exposure to valproic acid has been found to be associated with an increased risk of autism spectrum disorder. 19 2 | METHODS
| Data source
This study was conducted using the French national health insurance information system (SNIIRAM), which consists of 2 French nationwide datasets linked by a unique patient identifier: the French national health insurance database (DCIR) and the French hospital discharge database (PMSI). French national health insurance covers the entire French population and is divided into several specific schemes, including the general scheme for salaried workers (87% of the population), the self-employed workers scheme (6%), the farmers scheme (5%), and other additional schemes covering the remaining 2%. 20 The DCIR database contains all individualized and anonymous health care claims reimbursed by French National Health Insurance.
These claims include, in particular, dispensed drugs and medical procedures. The DCIR database also collects patient data such as age, gender, and eligibility for 100% health insurance coverage for serious and 
| Algorithm
Pregnancies were identified on the basis of their outcome from the DCIR database for outpatient medical abortions and from the PMSI database for all other pregnancy outcomes. The algorithm searched the databases for discharge diagnoses and medical procedures indicative of completion of a pregnancy coded between 2007 and 2015.
Diagnoses and procedures are presented in Table 1 . All records associated with unknown women identifiers, which could not be linked to any other data, were discarded. A flowchart describing the algorithm is available in Supporting Information (supplementary figure 1 ).
In the first step, all records of codes indicative of completion of a pregnancy in the PMSI database were grouped into 2 categories: (1) births (end of pregnancy ≥22 weeks after the last menstrual period
[LMP]); (2) any terminations of pregnancy <22 weeks after the LMP.
Codes representing the same pregnancy were then removed: for each woman, duplicate records were addressed separately in the 2 groups by choosing the last code as the pregnancy outcome within a predetermined time-frame. A 28-week span was used for births, and
KEY POINTS
• Access to claims databases provides an opportunity to study medication use and safety during pregnancy.
• Few articles have been specifically devoted to identification of pregnancies in claims databases, and no algorithms based on the French health care databases have been published.
• We have developed an algorithm that captured all types of pregnancy outcome and accurately identified pregnancy episodes.
• Among 7 559 701 pregnancies starting between 2007 and 2014, 6.7 per 1000 pregnancies were exposed to an AED. a 6-week span was used for terminations of pregnancy, as consecutive pregnancies within these time-frames were deemed implausible. 21 In the second step, all records of codes related to outpatient medical abortions were identified in the DCIR database, and duplicate records were addressed in a similar way to duplicate records of terminations of pregnancy in the PMSI database. Only outpatient medical abortions performed outside a 6-week span before and after a termination of pregnancy identified in the first step were included.
In the third step, terminations of pregnancy occurring during a pregnancy resulting in a birth were excluded. Terminations of pregnancy occurring during the first 10 weeks after a birth were also excluded. 21 Pregnancy outcomes were finally categorized into live births, stillbirths, elective abortions (both inpatient and outpatient), therapeutic abortions, spontaneous abortions, ectopic pregnancies, and other outcomes (hydatidiform mole or other abnormal products of conception).
| Pregnancy start date
Pregnancy start dates were calculated from the following: were available in the PMSI database, and the outcome date was considered to be the fifteenth day of the discharge month. Note:
Stillbirth = death of a fetus with a gestational age ≥ 22 weeks after the LMP or with a birth weight ≥ 500 g.
Spontaneous abortion = death of a fetus with a gestational age < 22 weeks after the LMP and a birth weight < 500 g.
Elective abortion = termination of pregnancy at the woman's request for reasons other than maternal health or fetal disease, possible until 14 weeks after the LMP in France. were therefore used to replace missing gestational ages or numbers of days after the LMP according to the type of pregnancy outcome. For this purpose, abortions were further detailed according to trimester and method (supplementary table 1 ).
This pregnancy start date was compared with an estimated conception date recorded in the DCIR database independently of the information available in the PMSI database. This estimated conception date is reported only for women entitled to maternity leave, which excludes all pregnancies ending before 22 weeks and self-employed workers, regardless of the pregnancy outcome.
| Comparison with official national data
The number of pregnancies identified by the algorithm was compared 
| Linkage between maternal and neonatal data
Linkage between maternal and neonatal data has been possible in the PMSI database since 2011 by means of a common identifier shared by the mother and her child and present in both the delivery stay and the birth stay. As a birth stay is coded in the PMSI database only for children with a gestational age ≥ 22 weeks after the LMP, this linkage is possible for live births, stillbirths, and therapeutic abortions after 22 weeks.
| Antiepileptic drug use
As women may have multiple pregnancies during the study period, the unit of analysis was a pregnancy. All pregnancies starting between 2007 and 2014, regardless of the outcome, were eligible for inclusion.
The mother had to have continuous health insurance enrolment for a 1-year period before pregnancy. The study was based on the national health insurance general scheme to ensure complete availability of data throughout the study period.
AEDs were defined according to the World Health Organization Anatomical Therapeutic Chemical classification (supplementary table   2 ). AEDs marketed before the early 1990s are traditionally referred to as "older" AED, whilst drugs that were introduced later are referred to as "newer" AED. 25 Women were considered to be exposed during the 30 days following dispensing.
Prevalence of AED use during pregnancy was assessed between 2007 and 2014. Prevalence was defined as the number of pregnancies exposed to AEDs per 1000 pregnancies. Prevalence rates were calculated overall, by drug group (older versus newer AEDs) and by Anatomical Therapeutic Chemical classes. Drug use was also described by trimester of pregnancy: day 0 to day 90 (first trimester), day 91 to day 181 (second trimester), and day 182 until delivery (third trimester). If a period of exposure began in a given trimester and carried over into the subsequent trimester, both trimesters were considered to be exposed. Trends were also investigated, especially for pregnant women with epilepsy, identified with LTD codes G40 and G41. All epileptic women without epilepsy recorded as an LTD were missed.
A sensitivity analysis was conducted to account for uncertainty in estimating the time period during which a woman was pregnant: a lower limit for prevalence rates was calculated using the 5 th percentile of gestational age instead of the median when gestational age was missing and an upper limit was calculated using the 95 th percentile of gestational age.
| RESULTS

| Algorithm
The algorithm identified 6 230 200 women who had 9 647 843 pregnancies between 2007 and 2015 ( Table 2) . Mean age at the end of pregnancy was 29.5 years. Live birth was the most common pregnancy outcome (73.9%), followed by elective abortion (17.2%), spontaneous abortion (4.2%), ectopic pregnancy (1.1%), therapeutic abortion (1.0%), and stillbirth (0.4%). From 2009 onwards, the estimated conception date available for women entitled to maternity leave was 
| Antiepileptic drug use
Over the study period, 7 559 701 pregnancies, representing 4 900 139 pregnant women, met the inclusion and exclusion criteria.
In this population, 6.7 per 1000 pregnancies were exposed to AEDs: This study presents 2 main limitations. First of all, although health care claims data can be exhaustive, readily available, and reasonably inexpensive, making them attractive for large-scale studies, they are not designed for research purposes, unlike registries or, more generally, ad hoc prospectively collected databases, and can be susceptible to misclassification. 20, 27 In our study, the proposed algorithm was based on ICD-10 diagnosis codes and medical procedure codes that may be subject to coding errors, and data from medical records could not be used to validate pregnancy outcomes. For instance, the excess number of therapeutic abortions identified by the algorithm could be explained by the omission of the diagnosis code "Problems related to unwanted pregnancy". However, as the PMSI database is used for planning and funding purposes and is subject to coding quality control, coding errors should therefore be limited.
In addition, some pregnancies may not have been identified, particularly anonymized abortions, which can be requested by minors 28 and which represented up to 8% of all elective abortions in 2014.
Spontaneous abortions which are not managed in hospital were also missed: the proportion of spontaneous abortions identified with the algorithm was 4.2%, while spontaneous abortion occurs in approximately 15% of all clinically recognized pregnancies. 29 A second limitation of this study is that exact pregnancy outcome dates were not available before 2009, which could result in imprecise pregnancy start dates. However, the overall prevalence of AED use in our study did not differ by more than 1.3% when the first day or last day of the month of discharge was used instead of the 15 th day.
Another source of uncertainty is the absence of recording of gestational age before 2010 for births and 2013 for other outcomes, requiring for instance the use of median gestational ages observed after 2013 in the PMSI database: exposure misclassification could not be ruled out, especially for drugs that are not used chronically like AEDs. 30 In particular, preterm deliveries could not be identified when gestational age was missing. Assigning the same median gestational age to all preterm or full-term live births therefore resulted in too long durations of pregnancy for preterm deliveries. However, the 5th percentile of gestational age was used in a sensitivity analysis and did not substantially change the results.
This algorithm was implemented in a population of almost 5 million women starting a pregnancy between 2007 and 2014. Over the study period, 6.7 per 1000 pregnancies were exposed to an AED, compared with 8.3 in a previous study based on a small sample of the SNIIRAM database. 16 The prevalence rate, restricted to live births, was 6.3 per 1000 pregnancies, which was higher than those observed in 7
European regions, with prevalence rates ranging from 4.3 in The
Netherlands to 6.0 in Wales. 31 However, these prevalence rates cannot be compared directly, as the indications for AEDs vary from 1 country to another. An American study based on administrative health plan data found that 2% of women who gave birth between 2001 and 2007 were exposed to an AED during pregnancy, but mainly for the treatment of psychiatric or pain disorders. 32 The decreased use of older AEDs and the increased use of newer AEDs between 2007 and 2014 were in line with worldwide trends. [32] [33] [34] In particular, the proportion of pregnancies exposed to valproic acid, the most teratogenic AED, 18 decreased between 2007 and 2014. 19, [33] [34] [35] [36] These trends could be explained by changes in practice guidelines and improved medical knowledge, but other explanations such as changes in population cannot be ruled out.
However, valproic acid use during pregnancy remained high in France, particularly during the first trimester of pregnancy, corresponding to the period of greatest risk for the teratogenic effects 
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